Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells

Drug resistance is the predominant cause of mortality in late-stage patients with ovarian cancer. Histone deacetylase inhibitors (HDACis) have emerged as a novel type of second line drug with high specificity for tumor cells, including ovarian cancer cells. However, HDACis usually exhibit relatively...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoli, Wang, Jiandong, Liu, Jia, Mo, Qingqing, Yan, Xiyun, Ma, Ding, Duan, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403387/
https://www.ncbi.nlm.nih.gov/pubmed/28454309
http://dx.doi.org/10.3892/ol.2017.5630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403387/
https://www.ncbi.nlm.nih.gov/pubmed/28454309
http://dx.doi.org/10.3892/ol.2017.5630

Ejemplares similares